Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients

A Lerbaek; Thomas Birk Kristiansen; TL Katzenstein; Lars Reinhardt Mathiesen; J Gerstoft; C Nielsen; Klaus Larsen; Jens Ole Nielsen; N Obel; AL Laursen; Susanne Dam Poulsen

doi:10.1080/00365540410019633

Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients

A Lerbaek, Thomas Birk Kristiansen, TL Katzenstein, Lars Reinhardt Mathiesen, J Gerstoft, C Nielsen, Klaus Larsen, Jens Ole Nielsen, N Obel, AL Laursen, Susanne Dam Poulsen

Department of Clinical Medicine

4 Citations (Scopus)

Abstract

Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients.Lerbaek A, Kristiansen TB, Katzenstein TL, Mathiesen L, Gerstoft J, Nielsen C, Larsen K, Nielsen JO, Obel N, Laursen AL, Nielsen SD. Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, Denmark. The aim of the present study was to explore the treatment effect of tenofovir as implemented in clinical practice. Data are presented on 34 patients. 11 patients had tenofovir added to a stable anti-retroviral treatment (ART) and 23 patients had drugs other than tenofovir. CD4 counts, HIV-RNA levels and genotypic resistance were determined at baseline and after 3 and 6 months. After initiation of tenofovir treatment, a mean decrease in HIV-RNA for all 34 patients was observed (-0.43 log1o copies/ml (+/- 1.22) and -0.49 log10 copies/ml (+/- 1.36) after 3 and 6 months, respectively, (p = 0.045)). However, the effect of tenofovir on HIV-RNA in the group of patients who had tenofovir added to a stable ART was limited, and the decrease in HIV-RNA was significantly higher in patients who had drugs other than tenofovir changed as well (p = 0.004 and p = 0.03 after 3 and 6 months, respectively). After initiation of tenofovir treatment, no significant increases in CD4 count were observed. All new NRTI-associated mutations could be explained by the background treatment. In conclusion, we observed a significant decrease in HIV-RNA only when tenofovir was prescribed, in conjunction with other anti-retroviral drugs, to patients on a failing highly active antiretroviral drug regimen (HAART).

Original language	English
Journal	Scandinavian Journal of Infectious Diseases
Volume	36
Issue number	4
Pages (from-to)	280-6
Number of pages	6
ISSN	0036-5548
DOIs	https://doi.org/10.1080/00365540410019633
Publication status	Published - 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/00365540410019633

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15198185&itool=iconabstr&query_hl=41&itool=pubmed_docsum

Cite this

Lerbaek, A., Kristiansen, T. B., Katzenstein, TL., Mathiesen, L. R., Gerstoft, J., Nielsen, C., Larsen, K., Nielsen, J. O., Obel, N., Laursen, AL., & Poulsen, S. D. (2004). Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients. Scandinavian Journal of Infectious Diseases, 36(4), 280-6. https://doi.org/10.1080/00365540410019633

Lerbaek, A, Kristiansen, TB, Katzenstein, TL, Mathiesen, LR, Gerstoft, J, Nielsen, C, Larsen, K, Nielsen, JO, Obel, N, Laursen, AL & Poulsen, SD 2004, 'Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients', Scandinavian Journal of Infectious Diseases, vol. 36, no. 4, pp. 280-6. https://doi.org/10.1080/00365540410019633

@article{696cf8275112456aaa7f30f980f70e3b,

title = "Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients",

abstract = "Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients.Lerbaek A, Kristiansen TB, Katzenstein TL, Mathiesen L, Gerstoft J, Nielsen C, Larsen K, Nielsen JO, Obel N, Laursen AL, Nielsen SD. Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, Denmark. The aim of the present study was to explore the treatment effect of tenofovir as implemented in clinical practice. Data are presented on 34 patients. 11 patients had tenofovir added to a stable anti-retroviral treatment (ART) and 23 patients had drugs other than tenofovir. CD4 counts, HIV-RNA levels and genotypic resistance were determined at baseline and after 3 and 6 months. After initiation of tenofovir treatment, a mean decrease in HIV-RNA for all 34 patients was observed (-0.43 log1o copies/ml (+/- 1.22) and -0.49 log10 copies/ml (+/- 1.36) after 3 and 6 months, respectively, (p = 0.045)). However, the effect of tenofovir on HIV-RNA in the group of patients who had tenofovir added to a stable ART was limited, and the decrease in HIV-RNA was significantly higher in patients who had drugs other than tenofovir changed as well (p = 0.004 and p = 0.03 after 3 and 6 months, respectively). After initiation of tenofovir treatment, no significant increases in CD4 count were observed. All new NRTI-associated mutations could be explained by the background treatment. In conclusion, we observed a significant decrease in HIV-RNA only when tenofovir was prescribed, in conjunction with other anti-retroviral drugs, to patients on a failing highly active antiretroviral drug regimen (HAART).",

author = "A Lerbaek and Kristiansen, {Thomas Birk} and TL Katzenstein and Mathiesen, {Lars Reinhardt} and J Gerstoft and C Nielsen and Klaus Larsen and Nielsen, {Jens Ole} and N Obel and AL Laursen and Poulsen, {Susanne Dam}",

year = "2004",

doi = "10.1080/00365540410019633",

language = "English",

volume = "36",

pages = "280--6",

journal = "Scandinavian Journal of Infectious Diseases",

issn = "0036-5548",

publisher = "Taylor & Francis",

number = "4",

}

TY - JOUR

T1 - Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients

AU - Lerbaek, A

AU - Kristiansen, Thomas Birk

AU - Katzenstein, TL

AU - Mathiesen, Lars Reinhardt

AU - Gerstoft, J

AU - Nielsen, C

AU - Larsen, Klaus

AU - Nielsen, Jens Ole

AU - Obel, N

AU - Laursen, AL

AU - Poulsen, Susanne Dam

PY - 2004

Y1 - 2004

N2 - Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients.Lerbaek A, Kristiansen TB, Katzenstein TL, Mathiesen L, Gerstoft J, Nielsen C, Larsen K, Nielsen JO, Obel N, Laursen AL, Nielsen SD. Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, Denmark. The aim of the present study was to explore the treatment effect of tenofovir as implemented in clinical practice. Data are presented on 34 patients. 11 patients had tenofovir added to a stable anti-retroviral treatment (ART) and 23 patients had drugs other than tenofovir. CD4 counts, HIV-RNA levels and genotypic resistance were determined at baseline and after 3 and 6 months. After initiation of tenofovir treatment, a mean decrease in HIV-RNA for all 34 patients was observed (-0.43 log1o copies/ml (+/- 1.22) and -0.49 log10 copies/ml (+/- 1.36) after 3 and 6 months, respectively, (p = 0.045)). However, the effect of tenofovir on HIV-RNA in the group of patients who had tenofovir added to a stable ART was limited, and the decrease in HIV-RNA was significantly higher in patients who had drugs other than tenofovir changed as well (p = 0.004 and p = 0.03 after 3 and 6 months, respectively). After initiation of tenofovir treatment, no significant increases in CD4 count were observed. All new NRTI-associated mutations could be explained by the background treatment. In conclusion, we observed a significant decrease in HIV-RNA only when tenofovir was prescribed, in conjunction with other anti-retroviral drugs, to patients on a failing highly active antiretroviral drug regimen (HAART).

AB - Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients.Lerbaek A, Kristiansen TB, Katzenstein TL, Mathiesen L, Gerstoft J, Nielsen C, Larsen K, Nielsen JO, Obel N, Laursen AL, Nielsen SD. Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, Denmark. The aim of the present study was to explore the treatment effect of tenofovir as implemented in clinical practice. Data are presented on 34 patients. 11 patients had tenofovir added to a stable anti-retroviral treatment (ART) and 23 patients had drugs other than tenofovir. CD4 counts, HIV-RNA levels and genotypic resistance were determined at baseline and after 3 and 6 months. After initiation of tenofovir treatment, a mean decrease in HIV-RNA for all 34 patients was observed (-0.43 log1o copies/ml (+/- 1.22) and -0.49 log10 copies/ml (+/- 1.36) after 3 and 6 months, respectively, (p = 0.045)). However, the effect of tenofovir on HIV-RNA in the group of patients who had tenofovir added to a stable ART was limited, and the decrease in HIV-RNA was significantly higher in patients who had drugs other than tenofovir changed as well (p = 0.004 and p = 0.03 after 3 and 6 months, respectively). After initiation of tenofovir treatment, no significant increases in CD4 count were observed. All new NRTI-associated mutations could be explained by the background treatment. In conclusion, we observed a significant decrease in HIV-RNA only when tenofovir was prescribed, in conjunction with other anti-retroviral drugs, to patients on a failing highly active antiretroviral drug regimen (HAART).

U2 - 10.1080/00365540410019633

DO - 10.1080/00365540410019633

M3 - Journal article

SN - 0036-5548

VL - 36

SP - 280

EP - 286

JO - Scandinavian Journal of Infectious Diseases

JF - Scandinavian Journal of Infectious Diseases

IS - 4

ER -

Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this